Lysosomal Storage Diseases Therapeutics Market, By Treatment (Enzyme Replacement Therapy (Stem Cell Therapy, Substrate Reduction Therapy, Others)), By Indication (Gaucher's Disease, Fabry Disease, Pompe’s Syndrome, Mucopolysaccharidosis, Others), By End U

Lysosomal Storage Diseases Therapeutics Market, By Treatment (Enzyme Replacement Therapy (Stem Cell Therapy, Substrate Reduction Therapy, Others)), By Indication (Gaucher's Disease, Fabry Disease, Pompe’s Syndrome, Mucopolysaccharidosis, Others), By End User (Hospitals, Clinics), and By Region (North America Latin America Europe Asia Pacific Middle East Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

The deficiency of enzymes that causes a specific disease condition called lysosomal storage disease includes diseases such as Fabry Disease, Gaucher disease, lysosomal acid lipase deficiency, mucopolysaccharidosis, Hunter syndrome, and Pompe disease. Enzyme replacement therapy involves intravenous administration of enzymes in order to correct the deficiency of enzymes. Enzyme replacement is associated with fewer side effects than other treatment methods. Enzymes are obtained from sources such as human cells, animal cells, and recombinant DNA technology. Enzyme replacement, although does not provide permanent cure, helps prevents permanent damage to the body caused due to deficiency of a specific enzyme. Treatment consists of weekly or monthly doses depending upon the disease.

Restraints of the Global Lysosomal Storage Diseases Therapeutics Market

Factors such as high cost associated with the enzyme replacement therapy and complex reimbursement scenario causing therapy to be excluded from coverage by insurers due to this being rare diseases, hamper growth of the market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global lysosomal storage diseases therapeutics market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

It profiles leading players in the global lysosomal storage diseases therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans

Key companies covered as a part of this study include Shire plc, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., Quest Diagnostics, and Amicus Therapeutics, Inc.

Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics

The global lysosomal storage diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

Global Lysosomal Storage Diseases Therapeutics Market, By Treatment:

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

Global Lysosomal Storage Diseases Therapeutics Market, By Indication:

Gaucher's Disease

Fabry Disease

Pompe’s Syndrome

Mucopolysaccharidosis

Others

Global Lysosomal Storage Diseases Therapeutics Market, By End User:

Hospitals

Clinics

Global Lysosomal Storage Diseases Therapeutics Market, By Geography:

North America

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe’s Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country:

U.S.

Canada

Europe

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe’s Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country:

U.K.

Germany

Italy

France

Spain

Russia

Rest of Europe

Asia Pacific

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe’s Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country:

China

India

Japan

ASEAN

Australia

South Korea

Rest of Asia Pacific

Latin America

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe’s Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Middle East:

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe’s Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country:

GCC

Israel

Rest of Middle East

Africa

By Treatment

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy

Others

By Indication

Gaucher's Diseases

Fabry Diseases

Pompe’s Syndrome

Mucopolysaccharidosis

Other

By End User

Hospitals

Clinics

By Country/Region:

Central Africa

South Africa

North Africa

Company Profiles

Shire plc*

Company Overview

Product Portfolio

Financial Performance

Key Strategies

Recent Developments

Pfizer, Inc.

Sanofi SA

BioMarin Pharmaceutical Inc

Actelion Ltd.

Raptor Pharmaceutical Corp.

Protalix Biotherapeutics Inc.

Amicus Therapeutics, Inc.

“*” marked represents similar segmentation in other categories in the respective section.


Table of Contents
Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Treatment
Market Snippet, By Indication
Market Snippet, By End User
Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Key Developments
Regulatory Scenario
PEST Analysis
Pipeline Analysis
Global Lysosomal Storage Diseases Therapeutics Market, By Treatment, 2019 – 2027 (US$ Mn)
Introduction
Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017–2027
Segment Trends
Enzyme Replacement Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Segment Trends
Stem Cell Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Segment Trends
Substrate Reduction Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Segment Trends
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Segment Trends
Global Lysosomal Storage Diseases Therapeutics Market, By Indication, 2019 – 2027 (US$ Mn)
Introduction
Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017–2027
Segment Trends
Gaucher's Disease
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Fabry Disease
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Pompe’s Syndrome
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Mucopolysaccharidosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Global Lysosomal Storage Diseases Therapeutics Market, By End User, 2019 – 2027 (US$ Mn)
Introduction
Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017–2027
Segment Trends
Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Global Lysosomal Storage Diseases Therapeutics Market, By Regions, 2019 – 2027 (US$ Mn)
Introduction
Market Share Analysis, 2019 and 2027 (%)
Y-o-Y Growth Analysis, 2017–2027
Segment Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
U.S.
Canada
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
North Africa
Central Africa
South Africa
Competitive Landscape
Company Profiles
Shire plc
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Pfizer, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi SA
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
BioMarin Pharmaceutical Inc
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Actelion Ltd.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Raptor Pharmaceutical Corp.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Protalix Biotherapeutics Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Amicus Therapeutics, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Section
References
Research Methodology
About us and Sales Contact
*Browse 28 market data tables and 24 figures on “Lysosomal Storage Diseases Therapeutics Market – Global forecast to 2027.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook